Establishing the carcinogenic risk of immunomodulatory drugs.
about
Is murine gammaherpesvirus-68 (MHV-68) a suitable immunotoxicological model for examining immunomodulatory drug-associated viral recrudescence?Anti-tumour effects of polysaccharides isolated from Artemisia annua L by inducing cell apoptosis and immunomodulatory anti-hepatoma effects of polysaccharides.Synthetic pharmacotherapy for lupus nephritis.The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.Cutaneous Squamous Cell Carcinomas in Solid Organ Transplant Recipients Compared With Immunocompetent Patients.
P2860
Establishing the carcinogenic risk of immunomodulatory drugs.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Establishing the carcinogenic risk of immunomodulatory drugs.
@en
Establishing the carcinogenic risk of immunomodulatory drugs.
@nl
type
label
Establishing the carcinogenic risk of immunomodulatory drugs.
@en
Establishing the carcinogenic risk of immunomodulatory drugs.
@nl
prefLabel
Establishing the carcinogenic risk of immunomodulatory drugs.
@en
Establishing the carcinogenic risk of immunomodulatory drugs.
@nl
P2860
P356
P1476
Establishing the carcinogenic risk of immunomodulatory drugs.
@en
P2093
James L Weaver
P2860
P304
P356
10.1177/0192623311427711
P407
P577
2011-11-21T00:00:00Z